Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Growth Hormone Signaling in Vivo in Humans

NCTNCT00512473 (opens ClinicalTrials.gov in a new tab)Other id20050113
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
8 participants (actual)
Sponsor
University of Aarhus · Other
Design
Randomized · Single masking
Countries
1 country

Denmark

Start
Sept 2005
Primary completion
Not stated
Completion
Apr 2006
First posted
7 Aug 2007 (estimated)
Last update posted
7 Aug 2007 (estimated)
Conditions
Intracellular Signaling Peptides and Proteins

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200520062007
  1. N/A

    Growth Hormone Signaling in Vivo in Humans

    NCT00512473

    Sept 2005 to Apr 2006

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Objective: GH induces insulin resistance in muscle and fat and in vitro data indicate that this may involve crosstalk between the signaling pathways of the two hormones. Aim: To investigate GH and insulin signaling in vivo in human muscle and fat tissue in response to GH, GH receptor blockade and insulin stimulation..

Interventions

  • Saline infusionDrug
  • Human Growth HormoneDrug
  • PegvisomantDrug

Arms3

  • Placebo comparator

    A

    I.v. saline for 8 hours

  • Experimental

    GH

    Growth hormone (0.5 mg s.c. at t = 0 hours)

  • Experimental

    Pegvisomant

    Pegvisomant injection 30 mg 36 hours prior to the study

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. GH-receptor signaling

    Time frame · hours

Secondary outcomes(1)

  1. Insulin sensitivity

    Time frame · hours

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2008

Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade.

Nielsen et al. 2008The Journal of clinical endocrinology and metabolismcited by 49

PMID 18460563DOI 10.1210/jc.2007-2414PUB-18460563

Rights unknown
Source link

Indexing hint: Randomized controlled trial · 2007

1 result

Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans.

Gormsen et al. 2007Clinical endocrinologycited by 23

PMID 17492951DOI 10.1111/j.1365-2265.2007.02786.xPUB-17492951

Rights unknown1 result
Source linkSee results (1)

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedGormsen LC, Nielsen C, Jessen N, Jorgensen JO, Moller N. Time-course effects of physiological free fatty acid surges on insulin sensitivity in humans. Acta Physiol (Oxf). 2011 Mar;201(3):349-56. doi: 10.1111/j.1748-1716.2010.02181.x. Epub 2010 Oct 11. PMID 20731625

Eligibility

Who could join, as posted.

Sex
Male
Age
from 20 Years up to 40 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Male * Healthy * Not taking medication Exclusion Criteria: * Insulin resistance

PepBank is a research reference. Talk to a doctor before you use any peptide.